<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The objective of the <z:mp ids='MP_0002055'>Diabetes</z:mp> Prevention Program (DPP) is to prevent or delay the development of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in those high-risk individuals who have tested positive for <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo> on an oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance test </plain></SENT>
<SENT sid="1" pm="."><plain>The DPP is a multicenter randomized clinical trial in the U.S. with three intervention arms--lifestyle, <z:chebi fb="0" ids="6801">metformin</z:chebi>, and placebo--with 1,000 participants in each arm who will be recruited over a 3-year recruitment period and will be followed for 3 years after the study-wide closing date for recruitment, resulting in a 3- to 6-year participant follow-up interval </plain></SENT>
<SENT sid="2" pm="."><plain>The primary outcome is the development of <z:mp ids='MP_0002055'>diabetes</z:mp> according to the revised American <z:mp ids='MP_0002055'>Diabetes</z:mp> Association criteria, confirmed with a repeat test </plain></SENT>
<SENT sid="3" pm="."><plain>Recruitment ended in the spring of 1999 </plain></SENT>
<SENT sid="4" pm="."><plain>As of 14 October 1998, the DPP had screened 133,683 individuals, of whom 26,518 had an oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance test, resulting in 3,048 randomized participants (585 of who were former <z:chebi fb="0" ids="9753">troglitazone</z:chebi> arm participants) </plain></SENT>
<SENT sid="5" pm="."><plain>Of the randomized participants, approximately 45% belong to an ethnic minority group, 67% are women, and 10% are &gt; or = 65 years old </plain></SENT>
<SENT sid="6" pm="."><plain>In conclusion, recruitment of subjects for the DPP has been highly successful, particularly with respect to recruitment of minority participants </plain></SENT>
</text></document>